ASX CEO Connect live online

DATE: Tuesday 22 October 2024
TIME: 10:00am - 11:45am AEDT
FORMAT: Virtual event
PRICE: Free

Managing Director, Nickel Industries (ASX:NIC)

Nickel Industries Limited (ASX:NIC) is an ASX-listed company which owns a portfolio of mining and low-cost downstream nickel processing assets in Indonesia.

The Company has a long history in Indonesia, with controlling interests in the world-class Hengjaya Mine, as well as four rotary kiln electric furnace (RKEF) projects which produce nickel matte for the electric vehicle (EV) supply chain and nickel pig iron (NPI) for the stainless-steel industry.

Having established itself as a globally significant producer of NPI, the Company is now rapidly transitioning its production to focus on the EV battery supply chain – recently, the Company has acquired a 10% interest in the Huayue Nickel Cobalt (HNC) HPAL project, adding mixed hydroxide precipitate (MHP) to its product portfolio.

Nickel Industries is now embarking on its next transformative step, investing in Excelsior Nickel Cobalt (ENC), a next-generation HPAL project capable of producing MHP, nickel sulphate and nickel cathode. ENC is expected to produce approximately 72,000 tonnes of nickel metal per annum, diversifying the Company’s production and reducing the Company’s carbon emissions profile – reflecting the strong commitment to sustainable operations.

Chief Executive Officer, Region Group (ASX:RGN)

Region Group (ASX:RGN) is an internally managed real estate investment trust (REIT) with 92 convenience-based retail properties valued at $4.4 billion. The Group has the largest convenience-based portfolio in in Australia, many of which have a strong weighting to food sales due to grocery-based anchors such as supermarkets. Region’s portfolio benefits from long-term leases to Woolworths Group Limited and Coles Group Limited, which act as anchor tenants at most of properties. Region is passionate about making life’s essentials easy and inspiring while enabling communities to thrive and grow.

Chief Executive Officer, Neuren Pharmaceuticals (ASX:NEU)

Neuren (ASX:NEU) is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. DAYBUE™ (trofinetide) is approved by the US Food and Drug Administration (FDA) for the treatment of Rett syndrome in adult and pediatric patients two years of age and older. Neuren has granted an exclusive worldwide licence to Acadia Pharmaceuticals Inc. for the development and commercialisation of trofinetide. Neuren’s second drug candidate, NNZ-2591, is in Phase 2 development for multiple neurodevelopmental disorders, with positive results achieved in Phase 2 clinical trials in Phelan-McDermid syndrome, Pitt Hopkins syndrome and Angelman syndrome.

Group Chief Financial Officer, Vulcan Energy Resources (ASX:VUL)

Founded in 2018, Vulcan's (ASX:VUL) ZERO CARBON LITHIUM™ Project aims to decarbonise lithium production by developing the world’s first dual lithium chemicals and renewable energy business with net zero greenhouse gas emissions. 

Dual-listed on both the ASX and the Frankfurt Stock Exchange, Vulcan’s Phase One of the Project is targeting 24,000 tonnes of lithium hydroxide production capacity per year, enough for approximately 500,000 electric vehicle batteries and representing a major step forward to a European green lithium supply chain.

dddddd

This email was sent to you from ASX Operations Pty Ltd. 20 Bridge Street, Sydney, NSW, 2000, Australia
Information and material to be presented at the seminar is for educational purposes only and does not constitute financial product or taxation advice. Investors should obtain independent advice before making investment decisions. No responsibility is accepted by ASX Limited ABN 98 008 624 691 and its related bodies corporate (“ASX”) for any loss arising in any way (including due to negligence) from anyone acting or refraining from acting as a result of information or material presented at the seminar.
© Copyright 2024 ASX Limited ABN 98 008 624 691. All Rights Reserved.
Privacy Policy